Hiroyuki Kagechika received his Bachelor and Ph.D. degrees from The University of Tokyo (Pharmaceutical Sciences), Japan, in 1989 and was an Associate Professor at the same university until 2004. Then he moved to Tokyo Medical and Dental University (TMDU), where he is currently a Professor in Institute of Biomaetrials and Bioengineering (IBB). From 2010-2015, he was appointed as the Dean of Graduate School of Biomedical Science, and since 2012, as the Vice Dean of Graduate School of Medical and Dental Sciences. From 2020, he was was appointed as the Director of Institute of Biomaterials and Bioengineering (IBB). He is the author of over 280 scientific publications. His major research interest is the medicinal chemistry of nuclear receptors, such as retinoid, vitamin D, steroid hormone receptors, as well as the orphan receptors, and developed various specific ligands by using novel and unique pharmacophore and bioisosters, including a drug for acute promyelocytic leukemia. He is also interested in the chemistry of aromatic amides with unique structures, which is useful for construction of functional aromatic molecules. He received several awards such as The Pharmaceutical Society of Japan (PSJ) Award for Young Scientists (1994), The Pharmaceutical Society of Japan (PSJ) Award for Drug Research and Development (2006), The Japanese Cancer Association-Chugai Academy for Advanced Oncology Award (2015), and The Vitamin Society of Japan Award (2016). Recently, he is a coordinator foe JSPS core-to-core program for Center of international research platform for biomedical science and drug discovery against intractable diseases.